The Relationship of Kidney Tubule Biomarkers with Brain Imaging in CKD Patients in SPRINT.

Urine biomarker concentrations reflecting kidney tubule injury and dysfunction were not associated with brain MRI measures.Higher eGFR was associated with lower total brain cerebral blood flow.This is the first evaluation of the relationship of kidney tubule biomarkers with brain imaging by MRI in patients with CKD.

Informations de copyright

Copyright © 2022 by the American Society of Nephrology.

Déclaration de conflit d'intérêts

D. Rifkin reports being a scientific advisor or member of American Journal of Kidney Diseases Editorial Board (feature editor), American Board of Internal Medicine Nephrology Exam Committee; and reports having other interests/relationships as Co-investigator, US site, Empagliflozin-KIDNEY study (pending). D.E. Weiner reports having consultancy agreements by participating in Medical Advisory Boards for Akebia (2020, 2021), Cara Therapeutics (2020), Janssen Biopharmaceuticals (2019), and Tricida (2019); reports receiving honoraria for Akebia, paid to DCI; reports receiving research funding from all compensation paid to AstraZeneca (site Principal Investigator (PI), completed 2020), CSL Behring (site PI, ongoing), Goldfinch Bio (site PI, ongoing), Janssen Biopharmaceuticals (site PI, completed 2019), Tufts MC, Dialysis Clinic, Inc. (site PI for trials contracted with Dialysis Clinic, Inc. [DCI] including Ardelyx, ongoing, and Cara Therapeutics, completed); reports receiving honoraria from the National Kidney Foundation for editorial positions at American Journal of Kidney Diseases and Kidney Medicine, Elsevier for royalties from the National Kidney Foundation's (NKF) Primer on Kidney Diseases; reports being a scientific advisor or member as Co-Editor-in-Chief, NKF Primer on Kidney Diseases, 8th Edition, Editor-in-Chief, Kidney Medicine, Medical Director of Clinical Research, Dialysis Clinic Inc., Member, American Society of Nephrology Quality and Policy Committees and American Society of Nephrology representative to Kidney Care Partners, Scientific Advisory Board, National Kidney Foundation; and reports having other interests/relationships as Chair, adjudications committee, Evaluation of Effect of TRC101 in Progression of CKD in Subjects with Metabolic Acidosis (VALOR-CKD Trial, George Institute, Clinical Research Organization [CRO], sponsored by Tricida), Member of the Data Monitoring Committee, “Feasibility of Hemodialysis with GARNET? In Chronic Hemodialysis Patients with a Bloodstream Infection” Trial (Avania CRO). J.H. Ix reports having consultancy agreements with Ardelyx, AstraZeneca, Bayer, Jnana, and Sanifit; reports receiving research funding from Baxter International; and reports being a scientific advisor or member of AlphaYoung. M. Marquine reports research funding from the National Institutes of Health. M.G. Shlipak reports having consultancy agreements with Cricket Health, Intercept Pharmaceuticals, University of Washington Cardiovascular Health Study, and Veterans Medical; reports receiving research funding from Bayer Pharmaceuticals; reports receiving honoraria from AstraZeneca, Bayer, and Boehringer Ingelheim; reports being a scientific advisor or member of American Journal of Kidney Disease, Journal of the American Society of Nephrology, and Circulation; and reports having other interests/relationships as Board Member, Northern California Institute for Research and Education. M. Kurella Tamura reports receiving honoraria from the American Federation for Aging Research; and reports being a scientific advisor or member of the Beeson External Advisory Committee, CJASN Editorial Board, and the Clin-Star Advisory Board. N.M. Pajewski reports having an ownership interest in Eyenovia and Ocuphire Pharma; and reports being a scientific advisor or member of Journal of the American Geriatrics Society. All remaining authors have nothing to disclose.